{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:52:58Z","timestamp":1770709978298,"version":"3.49.0"},"reference-count":58,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["302637\/2017-6"],"award-info":[{"award-number":["302637\/2017-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["420276\/2016-5"],"award-info":[{"award-number":["420276\/2016-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["307191\/2016-8"],"award-info":[{"award-number":["307191\/2016-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2018\/08585-1"],"award-info":[{"award-number":["2018\/08585-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Cryptococcus neoformans is an encapsulated yeast responsible for more than 180,000 deaths per year. The standard therapeutic approach against cryptococcosis is a combination of amphotericin B with flucytosine. In countries where cryptococcosis is most prevalent, 5-fluorocytosine is rarely available, and amphotericin B requires intravenous administration. C. neoformans biofilm formation is related to increased drug resistance, which is an important outcome for hospitalized patients. Here, we describe new molecules with anti-cryptococcal activity. A collection of 66 semisynthetic derivatives of ursolic acid and betulinic acid was tested against mature biofilms of C. neoformans at 25 \u00b5M. Out of these, eight derivatives including terpenes, benzazoles, flavonoids, and quinolines were able to cause damage and eradicate mature biofilms. Four terpene compounds demonstrated significative growth inhibition of C. neoformans. Our study identified a pentacyclic triterpenoid derived from betulinic acid (LAFIS13) as a potential drug for anti-cryptococcal treatment. This compound appears to be highly active with low toxicity at minimal inhibitory concentration and capable of biofilm eradication.<\/jats:p>","DOI":"10.3390\/biom9120831","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T11:16:23Z","timestamp":1575544583000},"page":"831","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Highly Active Triterpene Derivative Capable of Biofilm Damage to Control Cryptococcus spp."],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-296X","authenticated-orcid":false,"given":"Maria E.","family":"Krummenauer","sequence":"first","affiliation":[{"name":"Centro de Biotecnologia, PPGBCM, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 91501-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6040-3704","authenticated-orcid":false,"given":"William","family":"Lopes","sequence":"additional","affiliation":[{"name":"Centro de Biotecnologia, PPGBCM, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 91501-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane W. A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Centro de Biotecnologia, PPGBCM, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 91501-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Schrank","sequence":"additional","affiliation":[{"name":"Centro de Biotecnologia, PPGBCM, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 91501-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8806-3182","authenticated-orcid":false,"given":"Simone C. B.","family":"Gnoatto","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90610-000, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Kawano","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual de Campinas, Campinas, S\u00e3o Paulo 13083-871, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-2300","authenticated-orcid":false,"given":"Marilene H.","family":"Vainstein","sequence":"additional","affiliation":[{"name":"Centro de Biotecnologia, PPGBCM, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 91501-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"Infectious Disease. How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Chapman, N., Doubell, A., Oversteegen, L., Chowdhary, V., and Rugarabamu, G. (2019, December 05). G-FINDER 2017. Neglected disease research and development: Reflecting on a decade of global investment. Available online: https:\/\/www.policycuresresearch.org\/g-finder-2017\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a019760","DOI":"10.1101\/cshperspect.a019760","article-title":"Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis","volume":"4","author":"Fraser","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3389\/fmicb.2017.02534","article-title":"Geometrical Distribution of Cryptococcus neoformans Mediates Flower-Like Biofilm Development","volume":"8","author":"Lopes","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Martinez, L., and Casadevall, A. (2015). Biofilm Formation by Cryptococcus neoformans. Microbiol. Spectrum., 3.","DOI":"10.1128\/microbiolspec.MB-0006-2014"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.fgb.2014.12.001","article-title":"Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs","volume":"78","author":"Krysan","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rodrigues, M.L. (2016). Funding and Innovation in Diseases of Neglected Populations: The Paradox of Cryptococcal Meningitis. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004429"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ostermann, H., Solano, C., Jarque, I., Garcia-Vidal, C., Gao, X., Barrueta, J.A., De Salas-Cansado, M., Stephens, J., Xue, M., and Weber, B. (2014). Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol. Toxicol., 15.","DOI":"10.1186\/2050-6511-15-52"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QCO.0b013e32832fa214","article-title":"Treatment of cryptococcal meningitis in resource limited settings","volume":"22","author":"Sloan","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IDR.S118892","article-title":"Fluconazole resistance in Candida species: A current perspective","volume":"10","author":"Berkow","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mmcr.2017.11.004","article-title":"Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis","volume":"19","author":"Mpoza","year":"2018","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bmcl.2017.12.060","article-title":"Semisynthesis, cytotoxicity, antimalarial evaluation and structure-activity relationship of two series of triterpene derivatives","volume":"28","author":"Cargnin","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1517\/13543784.2012.727395","article-title":"Terpenoids: Natural products for cancer therapy","volume":"21","author":"Huang","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.biopha.2017.09.115","article-title":"Antinflammatory and anticancer effects of terpenes from oily fractions of Teucruim alopecurus, blocker of IkappaBalpha kinase, through downregulation of NF-kappaB activation, potentiation of apoptosis and suppression of NF-kappaB-regulated gene expression","volume":"95","author":"Guesmi","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Silva, G.N.S.D., Primon-Barros, M., Macedo, A.J., and Gnoatto, S.C.B. (2019). Triterpene Derivatives as Relevant Scaffold for New Antibiofilm Drugs. Biomolecules, 9.","DOI":"10.3390\/biom9020058"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1128\/AAC.50.3.1021-1033.2006","article-title":"Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro","volume":"50","author":"Martinez","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fmicb.2017.00535","article-title":"The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against","volume":"8","author":"Joffe","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1128\/AAC.00376-07","article-title":"Voriconazole inhibits melanization in Cryptococcus neoformans","volume":"51","author":"Martinez","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1128\/iai.55.8.1751-1754.1987","article-title":"Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans","volume":"55","author":"Wickes","year":"1987","journal-title":"Infect. Immun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/21505594.2015.1066962","article-title":"Fungal serotype-specific differences in bacterial-yeast interactions","volume":"6","author":"Abdulkareem","year":"2015","journal-title":"Virulence"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijantimicag.2016.06.012","article-title":"Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus","volume":"48","author":"Lai","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Stoddart, M.J. (2011). Mammalian Cell Viability: Methods and Protocols, Humana Press\/Springer.","DOI":"10.1007\/978-1-61779-108-6"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gilbert, D.F., and Friedrich, O. (2018). Cell Viability Assays: Methods and Protocols. Humana Press.","DOI":"10.1007\/978-1-4939-6960-9"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lim, W., Melse, Y., Konings, M., Phat Duong, H., Eadie, K., Laleu, B., Perry, B., Todd, M.H., Ioset, J.R., and van de Sande, W.W.J. (2018). Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma. PLoS Negl. Trop. Dis., 12.","DOI":"10.1101\/258905"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0898-5529(90)90156-3","article-title":"Automatic generation of 3D-atomic coordinates for organic molecules","volume":"3","author":"Gasteiger","year":"1990","journal-title":"Tetrahedron Comput. Methodol."},{"key":"ref_29","first-page":"1000","article-title":"Comparison of automatic three-dimensional model builders using 639 X-Ray structures","volume":"34","author":"Sadowski","year":"1994","journal-title":"J. Chem. Inf. Model."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1021\/ja00299a024","article-title":"Development and use of quantum mechanical molecular models. 76. AM1: A new general-purpose quantum mechanical molecular model","volume":"107","author":"Dewar","year":"1985","journal-title":"J. Am. Chem. Soc."},{"key":"ref_31","unstructured":"Waterbeemd, H., Testa, B., Mannhold, R., Kubinyi, H., and Folkers, G. (2004). Drug bioavailability: Estimation of solubility, permeability, absorption and bioavailability, Wiley-VCH Verlag GmbH & Co. KGaA."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15376510701857320","article-title":"In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for windows, meteor, and vitic","volume":"18","author":"Marchant","year":"2008","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.bmc.2006.01.016","article-title":"Antifungal properties of new series of quinoline derivatives","volume":"14","author":"Musiol","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.micres.2009.09.002","article-title":"Antibacterial, antifungal, and antiviral activities of some flavonoids","volume":"165","author":"Orhan","year":"2010","journal-title":"Microbiol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijantimicag.2008.01.028","article-title":"In vitro activity of terpenes against Candida biofilms","volume":"31","author":"Dalleau","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cbi.2018.03.014","article-title":"SERCA plays a crucial role in the toxicity of a betulinic acid derivative with potential antimalarial activity","volume":"287","author":"Diedrich","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.3390\/molecules171012003","article-title":"Synthesis and antiplasmodial activity of betulinic acid and ursolic acid analogues","volume":"17","author":"Innocente","year":"2012","journal-title":"Molecules"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/cmi.12590","article-title":"Cryptococcal therapies and drug targets: The old, the new and the promising","volume":"18","author":"Coelho","year":"2016","journal-title":"Cell Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0000000000000812","article-title":"Effects of tenofovir and amphotericin B deoxycholate co-administration on kidney function in patients treated for cryptococcal meningitis","volume":"71","author":"Kiggundu","year":"2016","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural Products as Sources of New Drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.drudis.2008.07.004","article-title":"Natural products in drug discovery","volume":"13","author":"Harvey","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1039\/c1np00033k","article-title":"Natural products and Pharma 2011: Strategic changes spur new opportunities","volume":"28","author":"Carter","year":"2011","journal-title":"Nat. Prod. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.ejmech.2011.07.057","article-title":"Natural products: An evolving role in future drug discovery","volume":"46","author":"Mishra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ja.2013.86","article-title":"Antibiotics in the clinical pipeline in 2013","volume":"66","author":"Butler","year":"2013","journal-title":"J. Antibiot."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Camacho, E., and Casadevall, A. (2018). Cryptococcal Traits Mediating Adherence to Biotic and Abiotic Surfaces. J. Fungi, 4.","DOI":"10.3390\/jof4030088"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_47","unstructured":"Bradley, W.G., Daroff, R.B., Fenischel, G.M., and Jankovic, J. (2004). Neurology in clinical practice: The neurological disorders, Butterworth Heinemann."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Nokhodchi, A., and Martin, G.P. (2015). Pulmonary drug delivery: Advances and challenges, John Wiley & Sons.","DOI":"10.1002\/9781118799536"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kerns, E.H., and Di, L. (2008). Drug-like properties: Concepts, structure design and methods, Academic Press.","DOI":"10.1016\/B978-012369520-8.50025-5"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Piscitelli, S.C., and Rodvold, K. (2005). Drug interactions in infectious diseases, Humana Press.","DOI":"10.1385\/1592599249"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/01480540601186994","article-title":"Review of the toxicology of three alkyl diamines","volume":"30","author":"Kennedy","year":"2007","journal-title":"Drug Chem. Toxicol."},{"key":"ref_53","unstructured":"NIOSH (2007). NIOSH Pocket Guide to Chemical Hazards: Piperazine hydrochloride, CDC."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bmj.287.6390.463","article-title":"Ethylenediamine and piperazine sensitivity","volume":"287","author":"Wright","year":"1983","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF01971831","article-title":"Relationships between structure and induction of hyaline droplet accumulation in the renal cortex of male rats by aliphatic and alicyclic hydrocarbons","volume":"64","author":"Bomhard","year":"1990","journal-title":"Arch. Toxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1091581817704379","article-title":"Salt Selection Matters: Differential Renal Toxicity With MDV1634.Maleate Versus MDV1634.2HCl","volume":"36","author":"Guha","year":"2017","journal-title":"Int. J. Toxicol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: Implications for improving outcomes","volume":"58","author":"Jarvis","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","unstructured":"Cronin, M.D.T., and Madden, J.C. (2010). In Silico Toxicology: Principles and Applications, RSC Publishing."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/12\/831\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:43Z","timestamp":1760190043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/12\/831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["biom9120831"],"URL":"https:\/\/doi.org\/10.3390\/biom9120831","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}